-- Highlights Study Design, Outcome Measures, and Baseline Patient Data in the Ongoing Avacopan ACCOLADE Phase II Trial in C3G -- Reinforces Therapeutic Potential of Chemokine Receptor 2 (CCR2) Inhibition in the Treatment of FSGS -- MOUNTAIN VIEW, Calif. , Nov.

-- Topline data from pivotal ADVOCATE Phase III trial of C5a receptor inhibitor avacopan in ANCA vasculitis expected mid-to-late fourth quarter -- -- Awarded $1 million grant from the U.S. Food and Drug Administration ( FDA ), to support the ACCOLADE Phase II trial of avacopan in C3 Glomerulopathy

MOUNTAIN VIEW, Calif. , Oct. 28, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that the Company's third quarter 2019 financial results will be released after market close on Monday, November 4, 2019 . ChemoCentryx executive management will host a conference call and

MOUNTAIN VIEW, Calif. , Sept. 24, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that it will host an R&D Day on Tuesday, October 1, 2019 beginning at 12:00 p.m. ET in New York City . Key therapeutic areas of focus for the R&D Day will be ANCA-Associated Vasculitis

MOUNTAIN VIEW, Calif. , Aug. 29, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences in September:              BioCentury Newsmakers in the Biotech

-- Topline data from pivotal ADVOCATE Phase III trial of C5a receptor inhibitor avacopan in ANCA Vasculitis on track for Q4 2019 -- -- Completed enrollment in LUMINA 1 Phase II trial of CCR2 inhibitor CCX140 in Focal Segmental Glomerulosclerosis (FSGS) -- -- Advancing three additional clinical

MOUNTAIN VIEW, Calif. , Aug. 01, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will present at the Canaccord Genuity 39th Annual Growth Conference on Thursday, August 8, 2019 at 9:30 a.m. ET .

MOUNTAIN VIEW, Calif. , July 31, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that the Company's second quarter 2019 financial results will be released after market close on Monday, August 5, 2019 . ChemoCentryx executive management will host a conference call and

MOUNTAIN VIEW, Calif. , June 11, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences in June: Raymond James Life Sciences and MedTech Conference Tuesday,

-- Succession of topline data readouts expected, starting with Pivotal ADVOCATE Phase III trial of C5a receptor inhibitor avacopan in ANCA Vasculitis in Q4 2019 -- -- Conference call today at 5:00 p.m. Eastern Time -- MOUNTAIN VIEW, Calif. , May 06, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc.